Clinical trials: Solid Tumor, completed
Neoplasms, Solid Tumors
A Trial Of SU14813 In Patients With Advanced Solid Malignancies
The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.
- Trial name
- NCT00982267
- Testing
- SU014813
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 77 people
- Sponsor
- Pfizer
Patients With Advanced Solid Tumor or Lymphoma
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
APG-115 is a novel, orally active small-molecule mouse double minute 2 homolog (MDM2) inhibitor. Mechanistically, APG-115 increases p53 and p21 overexpression, activates p53 - mediated apoptosis in tumor cells retaining wild-type…
- Trial name
- APG-115 (NCT02935907)
- Testing
- APG-115
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascentage Pharma Group Inc.
Solid Tumors
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT00390936
- Testing
- Brivanib
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients…
- Trial name
- NCT03545971
- Testing
- IBI310, Sintilimab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel in Treating Older Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of paclitaxel in treating older patients who have solid…
- Trial name
- NCT00003092
- Testing
- paclitaxel
- Where
- 32 sites in United States
- Volunteers
- 120 people
- Sponsor
- Alliance for Clinical Trials in Oncology
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Solid Tumor
Text-based Intervention to Minimize the Time Burden of Routine Cancer Care
The primary objective is to test whether a text-based e-triage can safely minimize the time associated with routine cancer care by identifying patients who can proceed directly to their immunotherapy infusion without a preceding…
- Conditions
- Cancer, Solid Tumor, Patient Empowerment, Telemedicine
- Trial name
- TIME (NCT05134636)
- Testing
- Text triage
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Solid Tumors, Virally Mediated Cancers and Liposarcoma
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
The purpose of this study is to determine whether 5-azacitidine in combination with romidepsin cancer are effective in the treatment of advanced solid tumors.
- Trial name
- NCT01537744
- Testing
- oral 5-azacitidine in combination with romidepsin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Positron-Emission Tomography, Immunomodulation
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to…
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Trial name
- NCT03107663
- Testing
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImaginAb, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372736
- Testing
- AEG35156, docetaxel, protein expression analysis
- Where
- 3 sites in Canada
- Volunteers
- 27 people
- Sponsor
- NCIC Clinical Trials Group
Unspecified Childhood Solid Tumor, Protocol Specific
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of aflibercept in treating young patients with relapsed or refractory solid tumors. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00622414
- Testing
- ziv-aflibercept
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.
- Trial name
- NCT03733587
- Testing
- GX-I7, Cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Genexine, Inc.
Tumor, Solid
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free…
- Trial name
- NCT03911557
- Testing
- Durvalumab and Tremelimumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- John L. Villano, MD, PhD
Unspecified Adult Solid Tumor, Protocol Specific
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00520000
- Testing
- Carboplatin, Abraxane
- Volunteers
- 47 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer, Head and Neck Cancer
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
- Conditions
- Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms
- Trial name
- NCT00437372
- Testing
- Sunitinib, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Unspecified Adult Solid Tumor, Protocol Specific
MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MEN-10755 in treating adults who have recurrent or…
- Trial name
- NCT00003028
- Testing
- sabarubicin
- Where
- 49 sites in Austria, Belgium and 12 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Tumor
ARQ 197 in Subjects With Metastatic Solid Tumors
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
- Trial name
- NCT00302172
- Testing
- ARQ 197
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Unspecified Adult Solid Tumor, Protocol Specific
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
RATIONALE: Diagnostic procedures, such as PET and MRI scans, may help to measure a patient's response to treatment. PURPOSE: This diagnostic trial is studying how well PET and/or MRI scans work in assessing changes in tumor blood…
- Trial name
- NCT00019565
- Testing
- magnetic resonance imaging, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or…
- Trial name
- NCT04235101
- Testing
- SYD985 + Niraparib
- Where
- 6 sites in Belgium, Netherlands and 1 more
- Volunteers
- 32 people
- Sponsor
- Byondis B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.